Page last updated: 2024-10-24

candesartan and Stroke

candesartan has been researched along with Stroke in 68 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

ExcerptRelevanceReference
"Scandinavian Candesartan Acute Stroke Trial was a randomized controlled and placebo-controlled trial of candesartan within 30 h of ischaemic or haemorrhagic stroke."9.22Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016)
"The Scandinavian Candesartan Acute Stoke Trial was a randomized- and placebo-controlled trial of candesartan in 2,029 patients with acute stroke and systolic blood pressure ≥140 mmHg."9.20Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015)
"SCAST was an international multicentre, randomized and placebo-controlled trial of candesartan in 2029 patients recruited within 30  h of acute ischaemic or haemorrhagic stroke."9.20Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months. ( Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2015)
"SCAST was a randomized- and placebo-controlled, double-masked trial of candesartan given for 7 days, in 2029 patients with acute stroke and systolic blood pressure ≥140 mm Hg."9.19Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2014)
"Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure."9.17Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013)
"There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure."9.15The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011)
"Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)."9.14Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009)
"The Scandinavian Candesartan Acute Stroke Trial is an international randomised, placebo-controlled, double-blind trial of candesartan in acute stroke."9.14Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). ( Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, G; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2010)
"In elderly patients with ISH, antihypertensive treatment based on the ARB candesartan resulted in a significant 42% RR reduction in stroke in comparison with other antihypertensive treatment, despite little difference in blood pressure reduction."9.11Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004)
"We have previously reported that angiotensin type 1 receptor (AT1R) blockade with candesartan exerts neurovascular protection after experimental cerebral ischemia."7.81Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. ( Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Soliman, S, 2015)
"Stroke is a leading cause of death and disability."7.81Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials. ( Doggrell, SA, 2004)
"The vascular protective effects of placebo, candesartan (1 mg kg(-1) per day) monotherapy, candesartan (1 mg kg(-1) per day) and amlodipine (1 mg kg(-1) per day) combination therapy, and candesartan (1 mg kg(-1) per day) and hydrochlorothiazide (HCTZ) (10 mg kg(-1) per day) combination therapy for 2 weeks were compared in stroke-prone, spontaneously hypertensive rats."7.77Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Shimosato, T; Takai, S, 2011)
"Head-to-head comparison suggests that treatment with aliskiren before and during cerebral ischemia is at least as effective as candesartan in double transgenic rats."7.76Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. ( Culman, J; Hocher, B; Mueller, S; Muller, DN; Pfab, T; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A; Zhao, Y, 2010)
" The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD."7.76Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010)
"This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion."7.76Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010)
"We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown."7.75Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009)
"To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat."7.74Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008)
" This study aimed to compare potential neuroprotective effects of systemic pretreatment with the angiotensin receptor blocker, candesartan, and the angiotensin-converting enzyme (ACE)-inhibitor, ramipril, in normotensive Wistar rats after focal cerebral ischemia, with special emphasis on the regulation of neurotrophins."7.74Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. ( Krikov, M; Müller, S; Thone-Reineke, C; Unger, T; Villringer, A, 2008)
"We have shown that candesartan decreases the acute stroke-induced elevation of mean arterial blood pressure (MAP) in Wistar rats and improves functional outcome."7.74Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. ( Elewa, HF; Fagan, SC; Johnson, MH; Kozak, A; Kozak, W, 2008)
"Excess salt, via oxidative stress, accelerates stroke, and angiotensin II, via AT1 receptor, plays a pivotal role in brain superoxide production of SHRSP by excess salt."7.73Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. ( Ioroi, T; Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Tanaka, T; Wanibuchi, H; Yamamoto, E; Zhan, Y, 2005)
"Stroke is a major cause of mortality and disability worldwide."6.49Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013)
"Ischemic stroke is a leading cause of disability."5.34Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. ( Hallevi, H; Hazan-Halevy, I; Paran, E, 2007)
"Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface."5.31Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001)
"Scandinavian Candesartan Acute Stroke Trial was a randomized controlled and placebo-controlled trial of candesartan within 30 h of ischaemic or haemorrhagic stroke."5.22Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016)
"The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of blood pressure-lowering treatment with candesartan in acute stroke."5.20Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC; Sandset, PM, 2015)
"The Scandinavian Candesartan Acute Stoke Trial was a randomized- and placebo-controlled trial of candesartan in 2,029 patients with acute stroke and systolic blood pressure ≥140 mmHg."5.20Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015)
"SCAST was an international multicentre, randomized and placebo-controlled trial of candesartan in 2029 patients recruited within 30  h of acute ischaemic or haemorrhagic stroke."5.20Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months. ( Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2015)
"The Scandinavian Candesartan Acute Stroke Trial (SCAST) showed no beneficial clinical effects of blood pressure lowering with the angiotensin receptor blocker candesartan in the acute phase of stroke."5.20Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. ( Bath, PM; Berge, E; Jusufovic, M; Karlson, BW; Sandset, EC, 2015)
"SCAST was a randomized- and placebo-controlled, double-masked trial of candesartan given for 7 days, in 2029 patients with acute stroke and systolic blood pressure ≥140 mm Hg."5.19Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2014)
"Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure."5.17Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013)
"The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of candesartan in acute stroke."5.16Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. ( Bath, PM; Berge, E; Kjeldsen, SE; Murray, GD; Sandset, EC, 2012)
"There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure."5.15The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011)
"The Scandinavian Candesartan Acute Stroke Trial is an international randomised, placebo-controlled, double-blind trial of candesartan in acute stroke."5.14Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). ( Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, G; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2010)
"Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)."5.14Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009)
"In elderly patients with ISH, antihypertensive treatment based on the ARB candesartan resulted in a significant 42% RR reduction in stroke in comparison with other antihypertensive treatment, despite little difference in blood pressure reduction."5.11Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004)
"The Study on COgnition and Prognosis in the Elderly (SCOPE) assessed the effect of candesartan on cardiovascular outcomes in elderly patients with mild to moderate hypertension."5.11The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. ( Elmfeldt, D; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2005)
"The introduction of Angiotensin II receptor blockers (ARB) in 1995 was another milestone in the pharmacological management of hypertension."4.82[Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. ( Battegay, E; Zeller, A, 2005)
"We have previously reported that angiotensin type 1 receptor (AT1R) blockade with candesartan exerts neurovascular protection after experimental cerebral ischemia."3.81Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. ( Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Soliman, S, 2015)
"Stroke is a leading cause of death and disability."3.81Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials. ( Doggrell, SA, 2004)
"Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension."3.79Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013)
" Candesartan suppressed the development of lipoatrophy and reduced the incidence of stroke at 20 weeks of age."3.79Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats. ( Inoue, T; Ito, H; Takemori, K, 2013)
"The vascular protective effects of placebo, candesartan (1 mg kg(-1) per day) monotherapy, candesartan (1 mg kg(-1) per day) and amlodipine (1 mg kg(-1) per day) combination therapy, and candesartan (1 mg kg(-1) per day) and hydrochlorothiazide (HCTZ) (10 mg kg(-1) per day) combination therapy for 2 weeks were compared in stroke-prone, spontaneously hypertensive rats."3.77Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Shimosato, T; Takai, S, 2011)
"This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion."3.76Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010)
" The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD."3.76Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010)
"Head-to-head comparison suggests that treatment with aliskiren before and during cerebral ischemia is at least as effective as candesartan in double transgenic rats."3.76Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. ( Culman, J; Hocher, B; Mueller, S; Muller, DN; Pfab, T; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A; Zhao, Y, 2010)
"We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown."3.75Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009)
"To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat."3.74Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008)
"We have shown that candesartan decreases the acute stroke-induced elevation of mean arterial blood pressure (MAP) in Wistar rats and improves functional outcome."3.74Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. ( Elewa, HF; Fagan, SC; Johnson, MH; Kozak, A; Kozak, W, 2008)
" Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury."3.74Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008)
" This study aimed to compare potential neuroprotective effects of systemic pretreatment with the angiotensin receptor blocker, candesartan, and the angiotensin-converting enzyme (ACE)-inhibitor, ramipril, in normotensive Wistar rats after focal cerebral ischemia, with special emphasis on the regulation of neurotrophins."3.74Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. ( Krikov, M; Müller, S; Thone-Reineke, C; Unger, T; Villringer, A, 2008)
"Excess salt, via oxidative stress, accelerates stroke, and angiotensin II, via AT1 receptor, plays a pivotal role in brain superoxide production of SHRSP by excess salt."3.73Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. ( Ioroi, T; Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Tanaka, T; Wanibuchi, H; Yamamoto, E; Zhan, Y, 2005)
" Perindopril, candesartan cilexetil, or amlodipine alone or the combination of low doses of each agent was administered orally to stroke-prone spontaneously hypertensive rats (SHRSP) for 4 weeks to compare the hypotensive or cardiovascular effects."3.70Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. ( Iwao, H; Izumi, Y; Kim, S; Zhan, Y, 2000)
"Candesartan was associated with improved whole brain CVR compared to placebo in the CEDAR study (adjusted within-group mean difference for candesartan = 0."3.01Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials. ( Hajjar, I; Henley, B; Kulshreshtha, A; Okafor, M; Trammell, A, 2023)
"Stroke is a major cause of mortality and disability worldwide."2.49Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013)
"The development of new treatments for acute stroke has been fraught with costly and spectacularly disappointing failures."2.46Drug repurposing for drug development in stroke. ( Fagan, SC, 2010)
"As stroke is characterised by vascular remodelling and dysfunction and by effects on the cerebral circulation, selecting an agent that has a direct vascular protective effect beyond blood pressure control may be desirable."2.42Stroke prevention: is it possible? If so, which antihypertensive agent should be used? ( Kim, S, 2003)
"Arterial hypertension is closely correlated with the occurrence of stroke and also with the loss of cognitive function and dementia."2.42Neurological protection provided by candesartan: reviewing the latest study results. ( Leys, D, 2003)
"Stroke is a leading cause of adult disability worldwide."1.46Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension. ( Ahmed, H; Alhusban, A; Ergul, A; Fagan, SC; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Sayed, MA, 2017)
"However, the endothelin-1 (ET-1)-induced middle cerebral artery occlusion (MCAO) model of cerebral ischaemia is thought to more closely mimic the temporal events of an embolic stroke."1.35Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. ( Katovich, MJ; Mecca, AP; O'Connor, TE; Sumners, C, 2009)
"Ischemic stroke is a leading cause of disability."1.34Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. ( Hallevi, H; Hazan-Halevy, I; Paran, E, 2007)
"Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface."1.31Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001)

Research

Studies (68)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's36 (52.94)29.6817
2010's31 (45.59)24.3611
2020's1 (1.47)2.80

Authors

AuthorsStudies
Henley, B1
Okafor, M1
Kulshreshtha, A1
Trammell, A1
Hajjar, I1
Alhusban, A2
Kozak, A5
Pillai, B4
Ahmed, H1
Sayed, MA1
Johnson, MH4
Ishrat, T5
Ergul, A6
Fagan, SC9
Culman, J3
Jacob, T1
Schuster, SO1
Brolund-Spaether, K1
Brolund, L1
Cascorbi, I1
Zhao, Y3
Gohlke, P2
Hornslien, AG3
Sandset, EC10
Bath, PM8
Wyller, TB2
Berge, E10
Antoniou, T1
Camacho, X1
Yao, Z1
Gomes, T1
Juurlink, DN1
Mamdani, MM1
Takemori, K1
Inoue, T1
Ito, H1
Kikuchi, K1
Tancharoen, S1
Ito, T1
Morimoto-Yamashita, Y1
Miura, N1
Kawahara, K1
Maruyama, I1
Murai, Y1
Tanaka, E1
Hafez, S1
Soliman, S2
Pillai, A1
Somanath, PR1
El-Remessy, AB2
Fouda, AY2
Jusufovic, M4
Karlson, BW1
Sandset, PM1
Igland, J1
Terént, A3
Boysen, G3
Murray, GD3
Abdul-Rahim, AH1
Perez, AC1
Fulton, RL1
Jhund, PS1
Latini, R1
Tognoni, G1
Wikstrand, J1
Kjekshus, J1
Lip, GY1
Maggioni, AP1
Tavazzi, L1
Lees, KR1
McMurray, JJ1
Eldahshan, W1
Waller, JL1
Kozak, W1
Elewa, HF2
Kato, N1
Liang, YQ1
Ochiai, Y1
Birukawa, N1
Serizawa, M1
Jesmin, S1
Machado, LS1
Abdelsaid, M1
Wiley, DC1
Kasanuki, H1
Hagiwara, N1
Hosoda, S1
Sumiyoshi, T1
Honda, T1
Haze, K1
Nagashima, M1
Yamaguchi, J1
Origasa, H1
Urashima, M1
Ogawa, H2
Mecca, AP1
O'Connor, TE1
Katovich, MJ1
Sumners, C1
Kjeldsen, SE3
Stålhammar, J1
Hasvold, P1
Bodegard, J1
Olsson, U1
Russell, D1
Saad, MA1
Abbas, AM1
Boshra, V1
Elkhateeb, M1
El Aal, IA1
Murray, G1
Jatuzis, D2
Kõrv, J2
Lüders, S3
Richter, PS2
Roine, RO2
Thijs, V2
Gaur, V1
Kumar, A1
Takai, S1
Jin, D1
Shimosato, T1
Sakonjo, H1
Miyazaki, M1
Schmerbach, K1
Pfab, T1
Mueller, S1
Villringer, A2
Muller, DN1
Hocher, B1
Unger, T2
Thoene-Reineke, C1
Hankey, GJ1
Hedner, T1
Narkiewicz, K1
Oparil, S1
Arima, H1
Chalmers, J1
Guan, W1
Castilla-Guerra, L1
Fernández-Moreno, MC1
Álvarez-Suero, J1
Jiménez Hernández, MD1
Kim, S3
Leys, D1
Mansour, J1
Peltier, M1
Oprisiu, R2
Achard, JM3
Fournier, A3
Christensen, H1
Doggrell, SA1
Schrader, J1
Diener, HC1
Kumagai, H1
Onami, T1
Takimoto, C1
Iigaya, K1
Saruta, T1
Williams, B1
Papademetriou, V2
Farsang, C1
Elmfeldt, D2
Hofman, A2
Lithell, H3
Olofsson, B2
Skoog, I2
Trenkwalder, P2
Zanchetti, A2
Lundkvist, J1
Ekman, M1
Kartman, B1
Carlsson, J1
Jönsson, L1
Kim-Mitsuyama, S2
Yamamoto, E2
Tanaka, T1
Zhan, Y2
Izumi, Y2
Izumiya, Y1
Ioroi, T1
Wanibuchi, H1
Iwao, H2
Zeller, A1
Battegay, E1
Suzuki, H3
Kanno, Y3
Nakamura, T3
Takenaka, T1
Kohara, K1
Brdon, J1
Kaiser, S1
Hagemann, F1
Serot, JM1
Black, SE1
Hallevi, H2
Hazan-Halevy, I1
Paran, E2
Kataoka, K1
Yamashita, T1
Tokutomi, Y1
Dong, YF1
Matsuba, S1
Rojas, A1
González, I1
Figueroa, H1
Hazan-Hallevi, I1
Krikov, M1
Thone-Reineke, C1
Müller, S1
Ikeda, Y1
Takano, H1
Kimura, H1
Obata, JE1
Takeda, S1
Hata, A1
Shido, K1
Mochizuki, S1
Yoshida, Y1
Jiménez, AM1
Montón, M1
García, R1
Núñez, A1
Gómez, J1
Rico, L1
García-Colis, E1
de Miguel, LS1
Arriero, MM1
Cabestrero, F1
Farré, J1
Casado, S1
López-Farré, A1
Dalmay, F1
Mazouz, H1
Allard, J1
Pesteil, F1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Scandinavian Candesartan Acute Stroke Trial[NCT00120003]Phase 32,500 participants (Anticipated)Interventional2005-06-30Completed
Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120]Phase 2200 participants (Anticipated)Interventional2021-03-02Not yet recruiting
A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655]500 participants (Anticipated)Interventional2017-01-31Completed
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349]Phase 4105 participants (Actual)Interventional2012-05-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

13 reviews available for candesartan and Stroke

ArticleYear
Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials.
    International journal of stroke : official journal of the International Stroke Society, 2023, Volume: 18, Issue:6

    Topics: Aged; Alzheimer Disease; Carbon Dioxide; Cognitive Dysfunction; Female; Humans; Lisinopril; Male; Ra

2023
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
    International journal of molecular sciences, 2013, Sep-13, Volume: 14, Issue:9

    Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Biphenyl Compou

2013
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart
    Circulation, 2015, Apr-28, Volume: 131, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds;

2015
Drug repurposing for drug development in stroke.
    Reviews in neurological diseases, 2010, Volume: 7 Suppl 1

    Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Discovery; Humans; Stroke

2010
Stroke prevention: is it possible? If so, which antihypertensive agent should be used?
    Current medical research and opinion, 2003, Volume: 19, Issue:5

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun

2003
Neurological protection provided by candesartan: reviewing the latest study results.
    Current medical research and opinion, 2003, Volume: 19, Issue:5

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2003
Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds

2004
[Organ protection by angiotensin II receptor blockers].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals;

2004
[Scope].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2004
Protection against stroke and dementia: an update on the latest clinical trial evidence.
    Current hypertension reports, 2004, Volume: 6, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl

2004
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Praxis, 2005, Apr-13, Volume: 94, Issue:15

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Ty

2005
[Study on cognition and prognosis in the elderly].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 6

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2006
[E-COST].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 6

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases

2006

Trials

17 trials available for candesartan and Stroke

ArticleYear
Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial.
    Stroke, 2013, Volume: 44, Issue:7

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Diso

2013
Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke.
    Stroke, 2014, Volume: 45, Issue:11

    Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Female; Huma

2014
Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:3

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com

2015
Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke.
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; D

2015
Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST).
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:6

    Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; F

2015
Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months.
    Journal of hypertension, 2015, Volume: 33, Issue:7

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphen

2015
Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST).
    Journal of hypertension, 2016, Volume: 34, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure

2016
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in
    European heart journal, 2009, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidaz

2009
Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003).
    International journal of stroke : official journal of the International Stroke Society, 2010, Volume: 5, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Hu

2010
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2011
Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome.
    Stroke, 2012, Volume: 43, Issue:8

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com

2012
Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds

2004
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
    Journal of the American College of Cardiology, 2004, Sep-15, Volume: 44, Issue:6

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2004
The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.
    Journal of human hypertension, 2005, Volume: 19, Issue:7

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds

2005
The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients.
    Blood pressure, 2005, Volume: 14, Issue:1

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds

2005
Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:4

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres

2005
An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C

2005

Other Studies

39 other studies available for candesartan and Stroke

ArticleYear
Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension.
    PloS one, 2017, Volume: 12, Issue:6

    Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds;

2017
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
    Naunyn-Schmiedeberg's archives of pharmacology, 2017, Volume: 390, Issue:9

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl

2017
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Sep-03, Volume: 185, Issue:12

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo

2013
Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats.
    Lipids in health and disease, 2013, Jul-22, Volume: 12

    Topics: Adipocytes; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl

2013
Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
    Neurochemical research, 2013, Volume: 38, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West

2013
Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 349, Issue:3

    Topics: Angiopoietin-1; Animals; Benzimidazoles; Biphenyl Compounds; Cell Culture Techniques; Cell Line; Cel

2014
Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats.
    Molecular neurobiology, 2015, Volume: 51, Issue:3

    Topics: Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Disease Models, Animal; Male; Neuronal

2015
Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke.
    Molecular neurobiology, 2017, Volume: 54, Issue:1

    Topics: Angiogenesis Inducing Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Benzim

2017
Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study.
    The Journal of pharmacology and experimental therapeutics, 2008, Volume: 326, Issue:3

    Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Hyper

2008
Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:10

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimida

2008
Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.
    Stroke, 2009, Volume: 40, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; Benzimidazoles; Biphenyl Compoun

2009
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
    Experimental physiology, 2009, Volume: 94, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia

2009
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
    Journal of human hypertension, 2010, Volume: 24, Issue:4

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F

2010
Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
    Acta physiologica Hungarica, 2010, Volume: 97, Issue:2

    Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor

2010
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
    Inflammopharmacology, 2011, Volume: 19, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Bi

2011
Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:2

    Topics: Acetylcholine; Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blo

2011
Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes.
    PloS one, 2010, Nov-29, Volume: 5, Issue:11

    Topics: Amides; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzimidaz

2010
Lowering blood pressure in acute stroke: the SCAST trial.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds

2011
Treatment of high blood pressure in acute stroke--the SCAST study.
    Blood pressure, 2011, Volume: 20, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; M

2011
Stroke: blood pressure lowering in acute stroke--scant joy from SCAST.
    Nature reviews. Cardiology, 2011, Apr-26, Volume: 8, Issue:7

    Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bip

2011
Drug repurposing for vascular protection after acute ischemic stroke.
    Acta neurochirurgica. Supplement, 2011, Volume: 111

    Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl C

2011
[In view of the findings of the SCAST study, must the treatment of arterial pressure in the acute phase of stroke be changed?].
    Revista de neurologia, 2011, Dec-16, Volume: 53, Issue:12

    Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topi

2011
[AT1 blocker therapy of hypertension in seniors. Added protection for cerebral blood vessels?].
    MMW Fortschritte der Medizin, 2003, Jan-16, Volume: 145, Issue:1-2

    Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds;

2003
The CHARM programme.
    Lancet (London, England), 2003, Nov-15, Volume: 362, Issue:9396

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme

2003
Hypertension in acute stroke.
    Archives of internal medicine, 2003, Nov-24, Volume: 163, Issue:21

    Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; Humans;

2003
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
    MMW Fortschritte der Medizin, 2003, Apr-10, Volume: 145, Issue:15

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds

2003
[Treating high blood pressure in acute stroke].
    MMW Fortschritte der Medizin, 2004, Mar-11, Volume: 146, Issue:11

    Topics: Acute Disease; Adrenergic alpha-Agonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve

2004
Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats.
    Stroke, 2005, Volume: 36, Issue:5

    Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphen

2005
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
    Journal of hypertension, 2007, Volume: 25, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure

2007
Treating stroke in the 21st century.
    Lancet (London, England), 2007, Mar-31, Volume: 369, Issue:9567

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Erythropoietin; Humans;

2007
Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
    European journal of neurology, 2007, Volume: 14, Issue:9

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cell Adhes

2007
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur

2008
Re: Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
    European journal of neurology, 2008, Volume: 15, Issue:2

    Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line, Transformed; Dipyridam

2008
The ECV-304 cell-line: should it be used?
    European journal of neurology, 2008, Volume: 15, Issue:2

    Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line; Dipyridamole; Endothel

2008
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
    Journal of hypertension, 2008, Volume: 26, Issue:3

    Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Brain-Derived

2008
Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:3

    Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting En

2000
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    The Journal of laboratory and clinical medicine, 2000, Volume: 135, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv

2000
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
    Journal of cardiovascular pharmacology, 2001, Volume: 37, Issue:4

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents

2001
Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2001, Volume: 2, Issue:2

    Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; B

2001